Clinical Trial Detail

NCT ID NCT03179410
Title PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC)
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Andrew J. Armstrong, MD
Indications

prostate cancer

Therapies

Avelumab

Age Groups: senior adult

No variant requirements are available.